4587N Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Peptidream News
4587N FAQ
What was Peptidream Inc.’s price range in the past 12 months?
Currently, no data Available
What is Peptidream Inc.’s market cap?
Peptidream Inc.’s market cap is $12.89B.
When is Peptidream Inc.’s upcoming earnings report date?
Peptidream Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 13 days.
How were Peptidream Inc.’s earnings last quarter?
Peptidream Inc. released its earnings results on May 13, 2026. The company reported -$0.706 earnings per share for the quarter, beating the consensus estimate of -$0.859 by $0.153.
Is Peptidream Inc. overvalued?
According to Wall Street analysts Peptidream Inc.’s price is currently Undervalued.
Does Peptidream Inc. pay dividends?
Peptidream Inc. does not currently pay dividends.
What is Peptidream Inc.’s EPS estimate?
Peptidream Inc.’s EPS estimate is -0.34.
How many shares outstanding does Peptidream Inc. have?
Peptidream Inc. has 130,010,400 shares outstanding.
What happened to Peptidream Inc.’s price movement after its last earnings report?
Peptidream Inc. reported an EPS of -$0.706 in its last earnings report, beating expectations of -$0.859. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Peptidream Inc.?
Currently, no hedge funds are holding shares in MX:4587N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Peptidream Inc.
PeptiDream Inc. functions as a biopharmaceutical enterprise, concentrating on the identification and progression of therapeutic compounds such as constrained peptides, small molecules, and peptide-drug conjugates. The company's unique product pipeline is underpinned by its proprietary Peptide Discovery Platform System (PDPS), an advanced technology specifically designed for the development of peptide-based drugs. Additionally, PeptiDream maintains an exclusive licensing and collaborative research partnership with Takeda Pharmaceutical Company Limited, aimed at creating peptide drug conjugates for the treatment of neuromuscular conditions. Established in 2006, the company's primary offices are situated in Kawasaki, Japan.